Clinical trials: Hepatitis A Virus
Colorectal Cancer Screening, Hepatitis C Virus
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75.
- Trial name
- MATCHES (NCT06745895)
- Testing
- MATCHES
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Opioid-Related Disorders, Hepatitis C (HCV)
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
This study will test the effectiveness, implementation outcomes, and cost effectiveness of a locally-tailored, health kiosk to reduce overdose, hepatitis C, and HIV risk behavior and improve linkage to care in rural Appalachia.
- Conditions
- Opioid-Related Disorders, Hepatitis C (HCV), Human Immunodeficiency Virus (HIV), Drug Overdose
- Trial name
- NCT05657106
- Testing
- Health kiosk
- Where
- United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- April M Young
HIV Testing, HEPATITIS C (HCV)
Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic
West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges.
- Conditions
- HIV Testing, HEPATITIS C (HCV), Syphilis, Hepatitis B Virus (HBV)
- Trial name
- NCT07317687
- Testing
- Rapid Fingerstick Test, Blood Draw for lab test
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West Virginia University
Hepatitis B Virus, Health Care Associated Infection
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
Hepatitis B virus (HBV) has infected over one third of the world's population; of these about 350 million go on to be chronic carriers.
- Trial name
- NCT04072211
- Testing
- Engerix-B
- Where
- Zambia
- Volunteers
- 641 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
Chronic Hepatitis B Virus Infection, Hepatitis B
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy.
- Trial name
- B-UNITED (NCT06537414)
- Testing
- Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen
- Where
- 80 sites in United States, Australia and 17 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Human Immunodeficiency Virus, HBV
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to…
- Conditions
- Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT02344680
- Testing
- Anti-HIV Agents
- Where
- Zambia
- Volunteers
- 349 people
- Sponsor
- University of Alabama at Birmingham
Chronic Hepatitis B Virus (Hbv)
A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
Existing nucleoside analogues (NAs) and interferon therapy for chronic hepatitis B (CHB) have limitations, including drug resistance, low HBsAg clearance rates, and irreversible immunosuppression.
- Trial name
- WGc0201-HBV (NCT07051187)
- Testing
- WGc0201
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiyan Liu
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
- Trial name
- NCT07037277
- Testing
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
- Where
- 107 sites in Egypt, France and 15 more
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis B Virus
NK Cell Deregulation in HBV Patients
Natural Killer (NK) cells play a large role in the innate immune response as they are equipped to kill infected or tumor cells. They express a panel of activating and inhibitory receptors that regulate the destruction of the…
- Trial name
- LiNKeB (NCT03761875)
- Testing
- blood sample CHB patients, boold sample Control group
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Hepatitis B Virus
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
Hepatitis B virus (HBV) infection constitutes a major public health threat worldwide. A total of 92 patients with HBeAg-negative chronic hepatitis B infection were recruited at Amiens University Hospital.
- Trial name
- HEPATITEB (NCT03625258)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B Virus Infection
Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection
Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks.
- Trial name
- NCT07519330
- Testing
- HH-006
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huahui Health
Chronic Hepatitis Delta Virus Infection
Expanded Access for Bulevirtide
The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).
- Trial name
- NCT06780579
- Testing
- Bulevirtide
- Sponsor
- Gilead Sciences
Hepatitis B Virus Infection
Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids
SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and…
- Trial name
- Flavonoids (NCT07084948)
- Testing
- Flavonoid, Tenofovir
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 134 people
- Sponsor
- Trieu, Nguyen Thi, M.D.
Hepatitis A, Hepatitis A Virus
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- HAV-2 (NCT06978621)
- Testing
- Inactivated hepatitis A vaccine (I-HAV)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Hepatitis A, Hepatitis A Virus
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- NCT07032610
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Chronic Hepatitis B Virus
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient.
- Trial name
- LiNKeB2 (NCT06853886)
- Testing
- blood sample HBV patient, blood sample healthy volunteers
- Where
- 3 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Hepatitis C Virus, Mutation Abnormality
Genotype and Subtype Mapping of the Hepatitis C Virus
Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States.
- Conditions
- Hepatitis C Virus, Mutation Abnormality, RNA Positive, Unusual Subtype
- Trial name
- CARTO-VHC (NCT07503288)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris